Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells

Leukemia and Lymphoma

Volumn 49, Issue 3, 2008, Pages 410-426

  Fotoohi, Alan Kambiz ^a   Albertioni, Freidoun ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

7 hydroxymethotrexate; Leukemia; Methotrexate; Resistance; Transport

Indexed keywords

7 HYDROXYMETHOTREXATE; ANTINEOPLASTIC ANTIMETABOLITE; BREAST CANCER RESISTANCE PROTEIN; CHLORAMPHENICOL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; ETOPOSIDE; FOLATE RECEPTOR; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; GLYCOPROTEIN P; LOMETREXOL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; PLEVITREXED; POLYGLUTAMINE; PYRIMETHAMINE; RALTITREXED; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE; THYMIDYLATE SYNTHASE; TRIMETREXATE; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CYTOTOXICITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INDIVIDUALIZATION; KIDNEY DYSFUNCTION; LEUKEMIA; LEUKEMIA CELL; MEMBRANE TRANSPORT; MUCOSA INFLAMMATION; PATIENT CARE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; HUMANS; LEUKEMIA; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE;

EID: 39749098413     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701824569     Document Type: Review

References (158)

1. Mitchell, H. K., Snell, E. E. and Williams, R. J. (1941) The concentration of "folic acid". J Am Chem Soc, 63, p. 2284.
2. Angier, R. B., Boothe, J. H. and Hutchings, B. L. (1945) Synthesis of a compound identical with the L. Casei factor. Science, 102, p. 227.
3. Heinley, R. W. and Welch, A. D. (1948) Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest, 27, p. 539.
4. Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F. and Wolff, J. A. (1948) Temporary remissions in acute leukemia produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med, 238, pp. 787-793.
5. Hertz, R., Lewis Jr, J. and Lipsett, M. B. (1961) Five year's experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol, 82, pp. 631-640.
6. Rustin, G. J., Rustin, F., Dent, J., Booth, M., Salt, S. and Bagshawe, K. D. (1983) No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med, 308, pp. 473-476.
7. Sonneveld, P., Schultz, F. W., Nooter, K. and Hahlen, K. (1986) Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate. Cancer Chemother Pharmacol, 18, pp. 111-116.
8. Jacobs, S. A., Stoller, R. G., Chabner, B. A. and Johns, D. G. (1976) 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest, 57, pp. 534-538.
9. Donehower, R. C., Hande, K. R., Drake, J. C. and Chabner, B. A. (1979) Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther, 26, pp. 63-72.
10. Evans, W. E., Pratt, C. B., Taylor, R. H., Barker, L. F. and Crom, W. R. (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol, 3, pp. 161-166.
11. Perez, C., Wang, Y. M., Sutow, W. W. and Herson, J. (1978) Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials, 1, pp. 107-111.
12. Stoller, R. G., Hande, K. R., Jacobs, S. A., Rosenberg, S. A. and Chabner, B. A. (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med, 297, pp. 630-634.
13. Albertioni, F., Rask, C., Eksborg, S., Poulsen, J. H., Pettersson, B. and Beck, O. (1996) Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin Chem, 42, pp. 39-44.
14. Fotoohi, K., Skarby, T., Soderhall, S., Peterson, C. and Albertioni, F. (2005) Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B Anal Technol Biomed Life Sci, 817, pp. 139-144.
15. Skarby, T. V., Anderson, H., Heldrup, J., Kanerva, J. A., Seidel, H. and Schmiegelow, K. (2006) High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia, 20, pp. 1955-1962.
16. Exadaktylos, P., Reiss, T., Schobess, R., Hommann, M., Hohne, S. and Beck, A. (1994) Acute hepatotoxicity with intermediate-dose methotrexate in children with leukemia and non-Hodgkin's lymphoma. Klin Padiatr, 206, pp. 315-318.
17. McIntosh, S., Davidson, D. L., O'Brien, R. T. and Pearson, H. A. (1977) Methotrexate hepatotoxicity in children with leukemia. J Pediatr, 90, pp. 1019-1021.
18. Perez, C., Sutow, W. W., Wang, Y. M. and Herson, J. (1979) Evaluation of overall toxicity of high-dosage methotrexate regimens. Med Pediatr Oncol, 6, pp. 219-228.
19. 2) in childhood malignancies: Clinical tolerability and pharmacokinetics. Pediatr Hematol Oncol, 4, pp. 33-42.
20. Fabre, G., Fabre, I., Matherly, L. H., Cano, J. P. and Goldman, I. D. (1984) Synthesis and properties of 7-hydroxymethotrexate polyglutamyl derivatives in Ehrlich ascites tumor cells in vitro. J Biol Chem, 259, pp. 5066-5072.
21. Fabre, G., Matherly, L. H., Favre, R., Catalin, J. and Cano, J. P. (1983) In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells. Cancer Res, 43, pp. 4648-4652.
22. Allegra, C. J., Hoang, K., Yeh, G. C., Drake, J. C. and Baram, J. (1987) Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem, 262, pp. 13520-13526.
23. Goldman, I. D., Lichtenstein, N. S. and Oliverio, V. T. (1968) Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem, 243, pp. 5007-5017.
24. Pao, S. S., Paulsen, I. T. and Saier Jr, M. H. (1998) Major facilitator superfamily. Microbiol Mol Biol Rev, 62, pp. 1-34.
25. Ferguson, P. L. and Flintoff, W. F. (1999) Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J Biol Chem, 274, pp. 16269-16278.
26. Matherly, L. H., Angeles, S. M. and Czajkowski, C. A. (1992) Characterization of transport-mediated methotrexate resistance in human tumor cells with antibodies to the membrane carrier for methotrexate and tetrahydrofolate cofactors. J Biol Chem, 267, pp. 23253-23260.
27. Dutta, B., Huang, W., Molero, M., Kekuda, R., Leibach, F. H. and Devoe, L. D. (1999) Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem, 274, pp. 31925-31929.
28. Eudy, J. D., Spiegelstein, O., Barber, R. C., Wlodarczyk, B. J., Talbot, J. and Finnell, R. H. (2000) Identification and characterization of the human and mouse SLC19A3 gene: A novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab, 71, pp. 581-590.
29. Rajgopal, A., Edmondnson, A., Goldman, I. D. and Zhao, R. (2001) SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta, 1537, pp. 175-178.
30. Goldman, I. D. (1971) The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci, 186, pp. 400-422.
31. Henderson, G. B. and Zevely, E. M. (1981) Anion exchange mechanism for transport of methotrexate in L1210 cells. Biochem Biophys Res Commun, 99, pp. 163-169.
32. Zhao, R., Gao, F., Wang, Y., Diaz, G. A., Gelb, B. D. and Goldman, I. D. (2001) Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem, 276, pp. 1114-1118.
33. Spinella, M. J., Brigle, K. E., Sierra, E. E. and Goldman, I. D. (1995) Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem, 270, pp. 7842-7849.
34. Goldman, I. D. and Matherly, L. H. (1985) The cellular pharmacology of methotrexate. Pharmacol Ther, 28, pp. 77-102.
35. Hill, B. T., Bailey, B. D., White, J. C. and Goldman, I. D. (1979) Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res, 39, pp. 2440-2446.
36. Sirotnak, F. M., Kurita, S. and Hutchison, D. J. (1968) On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia. Cancer Res, 28, pp. 75-80.
37. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I. and Bunni, M. (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem, 273, pp. 30189-30198.
38. Gorlick, R., Goker, E., Trippett, T., Steinherz, P., Elisseyeff, Y. and Mazumdar, M. (1997) Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89, pp. 1013-1018.
39. Trippett, T., Schlemmer, S., Elisseyeff, Y., Goker, E., Wachter, M. and Steinherz, P. (1992) Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood, 80, pp. 1158-1162.
40. Brigle, K. E., Spinella, M. J., Sierra, E. E. and Goldman, I. D. (1995) Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J Biol Chem, 270, pp. 22974-22979.
41. Roy, K., Tolner, B., Chiao, J. H. and Sirotnak, F. M. (1998) A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J Biol Chem, 273, pp. 2526-2531.
42. Rothem, L., Aronheim, A. and Assaraf, Y. G. (2003) Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem, 278, pp. 8935-8941.
43. Rothem, L., Stark, M. and Assaraf, Y. G. (2004) Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol Pharmacol, 66, pp. 1536-1543.
44. Fotoohi, K., Jansen, G., Assaraf, Y. G., Rothem, L., Stark, M. and Kathmann, I. (2004) Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy. Blood, 104, pp. 4194-4201.
45. Grant, S. C., Kris, M. G., Young, C. W. and Sirotnak, F. M. (1993) Edatrexate, an antifolate with antitumor activity: A review. Cancer Invest, 11, pp. 36-45.
46. Sirotnak, F. M. (1987) Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention. NCI Monogr, 5, pp. 27-35.
47. Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N. and Nakagomi, R. (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120, pp. 1689-1699.
48. Hakala, M. T. (1965) On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochim Biophys Acta, 102, pp. 210-225.
49. Schlemmer, S. R. and Sirotnak, F. M. (1992) Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles. J Biol Chem, 267, pp. 14746-14752.
50. Schlemmer, S. R. and Sirotnak, F. M. (1995) Structural preferences among folate compounds and their analogues for ATPase-mediated efflux by inside-out plasma membrane vesicles derived from L1210 cells. Biochem Pharmacol, 49, pp. 1427-1433.
51. Masuda, M., I'Izuka, Y., Yamazaki, M., Nishigaki, R., Kato, Y. and Ni'inuma, K. (1997) Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res, 57, pp. 3506-3510.
52. Ito, K., Oleschuk, C. J., Westlake, C., Vasa, M. Z., Deeley, R. G. and Cole, S. P. (2001) Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J Biol Chem, 276, pp. 38108-38114.
53. Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J. and Noordhuis, P. (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res, 59, pp. 2532-2535.
54. Lee, K., Klein-Szanto, A. J. and Kruh, G. D. (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Natl Cancer Inst, 92, pp. 1934-1940.
55. Zeng, H., Chen, Z. S., Belinsky, M. G., Rea, P. A. and Kruh, G. D. (2001) Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res, 61, pp. 7225-7232.
56. Chen, Z. S., Lee, K., Walther, S., Raftogianis, R. B., Kuwano, M. and Zeng, H. (2002) Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res, 62, pp. 3144-3150.
57. Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M. and Smith, A. J. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA, 96, pp. 6914-6919.
58. Dano, K. (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta, 323, pp. 466-483.
59. Juliano, R. L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, pp. 152-162.
60. Arkin, H., Ohnuma, T., Kamen, B. A., Holland, J. F. and Vallabhajosula, S. (1989) Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res, 49, pp. 6556-6561.
61. de Graaf, D., Sharma, R. C., Mechetner, E. B., Schimke, R. T. and Roninson, I. B. (1996) P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA, 93, pp. 1238-1242.
62. Gifford, A. J., Kavallaris, M., Madafiglio, J., Matherly, L. H., Stewart, B. W. and Haber, M. (1998) P-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier gene. Int J Cancer, 78, pp. 176-181.
63. Dietel, M., Arps, H., Lage, H. and Niendorf, A. (1990) Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res, 50, pp. 6100-6106.
64. Nakagawa, M., Schneider, E., Dixon, K. H., Horton, J., Kelley, K. and Morrow, C. (1992) Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res, 52, pp. 6175-6181.
65. Taylor, C. W., Dalton, W. S., Parrish, P. R., Gleason, M. C., Bellamy, W. T. and Thompson, F. H. (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer, 63, pp. 923-929.
66. Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L. and Fojo, A. T. (1990) Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem, 265, pp. 10073-10080.
67. Lee, J. S., Scala, S., Matsumoto, Y., Dickstein, B., Robey, R. and Zhan, Z. (1997) Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem, 65, pp. 513-526.
68. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y. and Rishi, A. K. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 95, pp. 15665-15670.
69. Volk, E. L., Rohde, K., Rhee, M., McGuire, J. J., Doyle, L. A. and Ross, D. D. (2000) Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res, 60, pp. 3514-3521.
70. Volk, E. L., Farley, K. M., Wu, Y., Li, F., Robey, R. W. and Schneider, E. (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res, 62, pp. 5035-5040.
71. Volk, E. L. and Schneider, E. (2003) Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res, 63, pp. 5538-5543.
72. Chen, Z. S., Robey, R. W., Belinsky, M. G., Shchaveleva, I., Ren, X. Q. and Sugimoto, Y. (2003) Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res, 63, pp. 4048-4054.
73. Rhee, M. S. and Schneider, E. (2005) Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochem Pharmacol, 69, pp. 123-132.
74. Kowalski, P., Stein, U., Scheffer, G. L. and Lage, H. (2002) Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther, 9, pp. 579-586.
75. McGuire, J. J. and Bertino, J. R. (1981) Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem, 38, pp. 19-48.
76. McBurney, M. W. and Whitmore, G. F. (1974) Isolation and biochemical characterization of folate deficient mutants of Chinese hamster cells. Cell, 2, pp. 173-182.
77. Jolivet, J., Schilsky, R. L., Bailey, B. D., Drake, J. C. and Chabner, B. A. (1982) Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest, 70, pp. 351-360.
78. Fabre, I., Fabre, G. and Goldman, I. D. (1984) Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res, 44, pp. 3190-3195.
79. Shih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C. and Habeck, L. L. (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res, 57, pp. 1116-1123.
80. Sanghani, S. P. and Moran, R. G. (1997) Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Biochemistry, 36, pp. 10506-10516.
81. Cowan, K. H. and Jolivet, J. (1984) A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem, 259, pp. 10793-10800.
82. Li, W. W., Lin, J. T., Tong, W. P., Trippett, T. M., Brennan, M. F. and Bertino, J. R. (1992) Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res, 52, pp. 1434-1438.
83. Lin, J. T., Tong, W. P., Trippett, T. M., Niedzwiecki, D., Tao, Y., Tan, C. and Steinherz, P. (1991) Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res, 15, pp. 1191-1196.
84. Rodenhuis, S., McGuire, J. J., Narayanan, R. and Bertino, J. R. (1986) Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res, 46, pp. 6513-6519.
85. Barredo, J. C., Synold, T. W., Laver, J., Relling, M. V., Pui, C. H. and Priest, D. G. (1994) Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood, 84, pp. 564-569.
86. Goker, E., Kheradpour, A., Waltham, M., Banerjee, D., Tong, W. P. and Elisseyeff, Y. (1995) Acute monocytic leukemia: A myeloid leukemia subset that may be sensitive to methotrexate. Leukemia, 9, pp. 274-276.
87. Argiris, A., Longo, G. S., Gorlick, R., Tong, W., Steinherz, P. and Bertino, J. R. (1997) Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia. Leukemia, 11, pp. 886-889.
88. Longo, G. S., Gorlick, R., Tong, W. P., Ercikan, E. and Bertino, J. R. (1997) Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood, 90, pp. 1241-1245.
89. Jansen, G., Schornagel, J. H., Kathmann, I., Westerhof, G. R., Hordijk, G. J. and van der Laan, B. F. (1992) Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res, 4, pp. 299-305.
90. Chen, L., Qi, H., Korenberg, J., Garrow, T. A., Choi, Y. J. and Shane, B. (1996) Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization, and differential splicing of its gene. J Biol Chem, 271, pp. 13077-13087.
91. Roy, K., Mitsugi, K. and Sirotnak, F. M. (1997) Additional organizational features of the murine folylpolyglutamate synthetase gene. Two remotely situated exons encoding an alternate 5[prime] end and proximal open reading frame under the control of a second promoter. J Biol Chem, 272, pp. 5587-5593.
92. Leclerc, G. J. and Barredo, J. C. (2001) Folylpoly-γ-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clin Cancer Res, 7, pp. 942-951.
93. Barrueco, J. R., O'Leary, D. F. and Sirotnak, F. M. (1992) Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds. J Biol Chem, 267, pp. 15356-15361.
94. Li, W. W., Waltham, M., Tong, W., Schweitzer, B. I. and Bertino, J. R. (1993) Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol, 338, pp. 635-638.
95. Rhee, M. S., Wang, Y., Nair, M. G. and Galivan, J. (1993) Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res, 53, pp. 2227-2230.
96. Pizzorno, G., Moroson, B. A., Cashmore, A. R., Russello, O., Mayer, J. R. and Galivan, J. (1995) Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res, 55, pp. 566-573.
97. Cole, P. D., Kamen, B. A., Gorlick, R., Banerjee, D., Smith, A. K. and Magill, E. (2001) Effects of overexpression of γ-Glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res, 61, pp. 4599-4604.
98. Longo, G. S., Gorlick, R., Tong, W. P., Lin, S., Steinherz, P. and Bertino, J. R. (1997) γ-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res, 9, pp. 259-263.
99. Rots, M. G., Pieters, R., Peters, G. J., Noordhuis, P., van Zantwijk, C. H. and Kaspers, G. J. (1999) Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood, 93, pp. 1677-1683.
100. Nimec, Z. and Galivan, J. (1983) Regulatory aspects of the glutamylation of methotrexate in cultured hepatoma cells. Arch Biochem Biophys, 226, pp. 671-680.
101. Johnson, T. B., Nair, M. G. and Galivan, J. (1988) Role of folylpolyglutamate synthetase in the regulation of methotrexate polyglutamate formation in H35 hepatoma cells. Cancer Res, 48, pp. 2426-2431.
102. Zhao, R., Gao, F. and Goldman, I. D. (2001) Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol, 61, pp. 857-865.
103. Balinska, M. (1986) Regulation of methotrexate polyglutaminate formation in Ehrlich ascites carcinoma cells by endogenous folate pool. Acta Biochim Pol, 33, pp. 31-37.
104. Balinska, M. (1988) Rescue effect of exogenous reduced folates on methotrexate polyglutamylation and dihydrofolate reductase activity in L1210 cells. Acta Biochim Pol, 35, pp. 199-205.
105. Assaraf, Y. G. and Goldman, I. D. (1997) Loss of folic acid exporter function with markedly augmented folate accumulation in lipophilic antifolate-resistant mammalian cells. J Biol Chem, 272, pp. 17460-17466.
106. Dixon, K. H., Trepel, J. B., Eng, S. C. and Cowan, K. H. (1991) Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. Cancer Commun, 3, pp. 357-365.
107. Rothem, L., Ifergan, I., Kaufman, Y., Priest, D. G., Jansen, G. and Assaraf, Y. G. (2002) Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem J, 367, pp. 741-750.
108. Morgan, S. L., Baggott, J. E., Vaughn, W. H., Austin, J. S., Veitch, T. A. and Lee, J. Y. (1994) Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med, 121, pp. 833-841.
109. Dijkmans, B. A. (1995) Folate supplementation and methotrexate. Br J Rheumatol, 34, pp. 1172-1174.
110. Wedge, S. R., Laohavinij, S., Taylor, G. A., Boddy, A., Calvert, A. H. and Newell, D. R. (1995) Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement. Clin Cancer Res, 1, pp. 1479-1486.
111. Calvert, H. (2002) Folate status and the safety profile of antifolates. Semin Oncol, 29, pp. 3-7.
112. Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J. and Chabner, B. A. (1983) The pharmacology and clinical use of methotrexate. N Engl J Med, 309, pp. 1094-1104.
113. Alt, F. W., Kellems, R. E. and Schimke, R. T. (1976) Synthesis and degradation of folate reductase in sensitive and methotrexate-resistant lines of S-180 cells. J Biol Chem, 251, pp. 3063-3674.
114. Alt, F. W., Kellems, R. E., Bertino, J. R. and Schimke, R. T. (1978) Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem, 253, pp. 1357-1370.
115. Srimatkandada, S., Medina, W. D., Cashmore, A. R., Whyte, W., Engel, D. and Moroson, B. A. (1983) Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry, 22, pp. 5774-5781.
116. Schimke, R. T. (1988) Gene amplification in cultured cells. J Biol Chem, 263, pp. 5989-5992.
117. Carman, M. D., Schornagel, J. H., Rivest, R. S., Srimatkandada, S., Portlock, C. S. and Duffy, T. (1984) Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol, 2, pp. 16-20.
118. Horns Jr, R. C., Dower, W. J. and Schimke, R. T. (1984) Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol, 2, pp. 2-7.
119. Trent, J. M., Buick, R. N., Olson, S., Horns Jr, R. C. and Schimke, R. T. (1984) Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. J Clin Oncol, 2, pp. 8-15.
120. Jackson, R. C., Hart, L. I. and Harrap, K. R. (1976) Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. Cancer Res, 36, pp. 1991-1997.
121. Simonsen, C. C. and Levinson, A. D. (1983) Isolation and expression of an altered mouse dihydrofolate reductase cDNA. Proc Natl Acad Sci USA, 80, pp. 2495-2499.
122. Melera, P. W., Davide, J. P., Hession, C. A. and Scotto, K. W. (1984) Phenotypic expression in Escherichia coli and nucleotide sequence of two Chinese hamster lung cell cDNAs encoding different dihydrofolate reductases. Mol Cell Biol, 4, pp. 38-48.
123. Miyachi, H., Takemura, Y., Kobayashi, H. and Ando, Y. (1995) Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate. Cancer Lett, 88, pp. 93-99.
124. McIvor, R. S. and Simonsen, C. C. (1990) Isolation and characterization of a variant dihydrofolate reductase cDNA from methotrexate-resistant murine L5178Y cells. Nucleic Acids Res, 18, pp. 7025-7032.
125. Van Triest, B., Pinedo, H. M., Giaccone, G. and Peters, G. J. (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol, 11, pp. 385-391.
126. Welsh, S. J., Titley, J., Brunton, L., Valenti, M., Monaghan, P. and Jackman, A. L. (2000) Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res, 6, pp. 2538-2546.
127. Ayusawa, D., Koyama, H. and Seno, T. (1981) Resistance to methotrexate in thymidylate synthetase-deficient mutants of cultured mouse mammary tumor FM3A cells. Cancer Res, 41, pp. 1497-1501.
128. O'Connor, B. M., Jackman, A. L., Crossley, P. H., Freemantle, S. E., Lunec, J. and Calvert, A. H. (1992) Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: A novel folate-based thymidylate synthase inhibitor. Cancer Res, 52, pp. 1137-1143.
129. Tong, Y., Liu-Chen, X., Ercikan-Abali, E. A., Capiaux, G. M., Zhao, S. C. and Banerjee, D. (1998) Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells. J Biol Chem, 273, pp. 11611-11618.
130. Kitchens, M. E., Forsthoefel, A. M., Barbour, K. W., Spencer, H. T. and Berger, F. G. (1999) Mechanisms of acquired resistance to thymidylate synthase inhibitors: The role of enzyme stability. Mol Pharmacol, 56, pp. 1063-1070.
131. Barbour, K. W., Hoganson, D. K., Berger, S. H. and Berger, F. G. (1992) A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2[prime]-deoxyuridine in mammalian and bacterial cells. Mol Pharmacol, 42, pp. 242-248.
132. Krajinovic, M., Costea, I. and Chiasson, S. (2002) Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet, 359, pp. 1033-1034.
133. Kumagai, K., Hiyama, K., Oyama, T., Maeda, H. and Kohno, N. (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med, 11, pp. 593-600.
134. Rocha, J. C., Cheng, C., Liu, W., Kishi, S., Das, S. and Cook, E. H. (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 105, pp. 4752-4758.
135. Tong, Y., Liu-Chen, X., Ercikan-Abali, E. A., Zhao, S. C., Banerjee, D. and Maley, F. (1998) Probing the folate-binding site of human thymidylate synthase by site-directed mutagenesis. Generation of mutants that confer resistance to raltitrexed, Thymitaq, and BW1843U89. J Biol Chem, 273, pp. 31209-31214.
136. Schwahn, B. and Rozen, R. (2001) Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics, 1, pp. 189-201.
137. Bailey, L. B. and Gregory III, J. F. (1999) Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: Metabolic significance, risks and impact on folate requirement. J Nutr, 129, pp. 919-922.
138. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A. and Matthews, R. G. (1995) A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, pp. 111-113.
139. Weisberg, I., Tran, P., Christensen, B., Sibani, S. and Rozen, R. (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab, 64, pp. 169-172.
140. van der Put, N. M., Gabreels, F., Stevens, E. M., Smeitink, J. A., Trijbels, F. J. and Eskes, T. K. (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?. Am J Hum Genet, 62, pp. 1044-1051.
141. Taub, J. W., Matherly, L. H., Ravindranath, Y., Kaspers, G. J., Rots, M. G. and Zantwijk, C. H. (2002) Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia, 16, pp. 764-765.
142. Schmeling, H., Biber, D., Heins, S. and Horneff, G. (2005) Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol, 32, pp. 1832-1836.
143. Liani, E., Rothem, L., Bunni, M. A., Smith, C. A., Jansen, G. and Assaraf, Y. G. (2003) Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer, 103, pp. 587-599.
144. Banerjee, D., Mayer-Kuckuk, P., Capiaux, G., Budak-Alpdogan, T., Gorlick, R. and Bertino, J. R. (2002) Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta, 1587, pp. 164-173.
145. Spencer, H. T., Sorrentino, B. P., Pui, C. H., Chunduru, S. K., Sleep, S. E. and Blakley, R. L. (1996) Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia, 10, pp. 439-446.
146. Li, W., Fan, J., Hochhauser, D., Banerjee, D., Zielinski, Z. and Almasan, A. (1995) Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA, 92, pp. 10436-10440.
147. Simonian, P. L., Grillot, D. A. and Nunez, G. (1997) Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood, 90, pp. 1208-1216.
148. Yeager, T. R. and Reznikoff, C. A. (1998) Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol, 159, pp. 581-585.
149. Costea, I., Moghrabi, A. and Krajinovic, M. (2003) The influence of cyclin D1 (CCND1) 870A > G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics, 13, pp. 577-580.
150. Krajinovic, M., Labuda, D., Mathonnet, G., Labuda, M., Moghrabi, A. and Champagne, J. (2002) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res, 8, pp. 802-810.
151. Davies, S. M., Bhatia, S., Ross, J. A., Kiffmeyer, W. R., Gaynon, P. S. and Radloff, G. A. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood, 100, pp. 67-71.
152. Breithaupt, H. and Kuenzlen, E. (1982) Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat Rep, 66, pp. 1733-1741.
153. Johns, D. G. and Loo, T. L. (1967) Metabolite of 4-amino-4-deoxy-N10-methylpteroylglutamic acid (methotrexate). J Pharm Sci, 56, pp. 356-359.
154. Redetzki, H. M., Redetzki, J. E. and Elias, A. L. (1966) Resistance of the rabbit tomethotrexate: Isolation of a drug metabolite with decreased cytotoxicity. Biochem Pharmacol, 15, pp. 425-433.
155. Lankelma, J., van der Klein, E. and Ramaekers, F. (1980) The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett, 9, pp. 133-142.
156. Drake, J. C., Allegra, C. J., Baram, J., Kaufman, B. T. and Chabner, B. A. (1987) Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochem Pharmacol, 36, pp. 2416-2418.
157. Pinkel, D., Hernandez, K., Borella, L., Holton, C., Aur, R. and Samoy, G. (1971) Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer, 27, pp. 247-256.
158. Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M. and Pui, C. H. (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med, 338, pp. 499-505.